Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Tipos de Cancer / Cánceres Pediátricos / Retinoblastoma / Recursos de NCI
National Cancer Institute®
Ultima Vez Modificado: 1 de febrero del 2002
1
UI - 11776612
AU - Zheng S; Ke Y
TI -
[Study of APC, Rb, c-met gene copy numbers of human gastric mucosa
epithelial cell line GES-1]
SO - Zhonghua Zhong Liu Za Zhi 1999 Nov;21(6):409-11
AD - Beijing Institute for Cancer Research, School of Oncology, Beijing
Medical University, Beijing 100034.
OBJECTIVE: To study the copy number of oncogene/tumor suppressor genes
in GES-1 cell line to identify its characteristics. METHODS: Bio-14-dATP
was incorporated into APC, Rb, c-met gene cloned in plasmid by nick
translation. Fluorescence in situ hybridization (FISH) of interphase
nuclei of GES-1 cells was performed. RESULTS: Two copies of APC were
shown in 48% interphase nuclei and 3 copies in 22%; 71% and 80% cells
had normal copies of Rb and c-met genes in their nuclei, respectively.
CONCLUSION: GES-1 cell line is a relatively normal gastric mucosa
epithelial cell line and can be used as a human in vitro model system
for the study of carcinogenesis.
2
UI - 11807886
AU - Tharapel SA; Kadandale JS
TI -
Primed in situ labeling (PRINS) for evaluation of gene deletions in
cancer.
SO - Am J Med Genet 2002 Jan 15;107(2):123-6
AD - Cytogenetics Reference Laboratory, Pathology and Laboratory Medicine
Service, V.A. Medical Center, Tennessee 38104, USA.
sugandhi.tharapel@med.va.gov
Rearrangements involving the 13q14 and 17p13 chromosomal regions are
often observed in leukemias and lymphomas. These rearrangements are not
always identifiable cytogenetically. In more than 50% of cases,
deletions occur at the submicroscopic level and the karyotypes appear
normal. Molecular cytogenetic techniques such as fluorescence in situ
hybridization (FISH) have accordingly contributed to the identification
of a variety of subtle rearrangements such as those involving
submicroscopic deletions. However, FISH is expensive, time consuming,
technically burdensome, and requires cloned DNA probes. A newer
technique, primed in situ labeling (PRINS), has been tested as a
possible alternative to FISH. To assess the utility and efficiency of
the PRINS method in the detection of RB1 and p53 deletions, we evaluated
10 patients with hematological disorders and known rearrangements, i.e.,
deletions involving 13q14 and 17p13 regions. The data in these cases
were validated against data obtained with standard FISH probes. Our
results indicate that PRINS could be used with relative ease in
cytogenetics laboratories and could serve as an alternative to
conventional FISH for defining deletions involving unique sequences.
Copyright 2001 Wiley-Liss, Inc.
3
UI - 11724429
AU - Ferri G; Colalongo C; Bini C; Pelotti S; Pappalardo G
TI -
DNA typing of hair shafts by microwave irradiation: real or deceptive
evidence?
SO - Int J Legal Med 2001 Oct;115(2):118-20
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Ms. Bruning talks about working in development for a cancer center and how this translates to hope in cancer care. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

